Literature DB >> 12643109

Drugs for cardiovascular risk reduction in the diabetic patient.

D S Bell1.   

Abstract

The diabetic patient is at increased risk for cardiac events. Lowering hemoglobin A1c levels even within the normal range is associated with less cardiac risk. Oral agents for diabetes that reduce insulin resistance and its associated cardiac risk factors in addition to lowering glucose should be used. Energetic reduction of blood pressure with an emphasis on the use of angiotensin-converting enzyme inhibitors and beta blockers will further reduce cardiac risk. Reduction of low-density lipoprotein and triglyceride levels and elevation of high-density lipoprotein levels through judicious use of statins and other anti-lipid agents is essential and will lower the rate of cardiac events in the diabetic patients even more than in the nondiabetic patients. In addition, aspirin and folic acid supplementation should be utilized. Use of a multiple risk factor management strategy with these drugs will lower morbidity and mortality, improve quality of life, and save cost for the diabetic patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12643109     DOI: 10.1007/s11892-001-0025-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  44 in total

Review 1.  Should angiotensin-converting enzyme inhibitors be added to the water supply of patients with diabetes?

Authors:  D S Bell
Journal:  Endocr Pract       Date:  2001 Jan-Feb       Impact factor: 3.443

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Why does the myocardium fail? Insights from basic science.

Authors:  M R Bristow
Journal:  Lancet       Date:  1998-08       Impact factor: 79.321

4.  Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.

Authors:  J S Yudkin; R D Forrest; C A Jackson
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

5.  Mortality from cardiovascular diseases among diabetics.

Authors:  A S Królewski; A Czyzyk; D Janeczko; J Kopczyński
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

6.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

Review 7.  Inflammation, insulin resistance, infection, diabetes, and atherosclerosis.

Authors:  D S Bell
Journal:  Endocr Pract       Date:  2000 May-Jun       Impact factor: 3.443

8.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

Authors:  M Fröhlich; A Imhof; G Berg; W L Hutchinson; M B Pepys; H Boeing; R Muche; H Brenner; W Koenig
Journal:  Diabetes Care       Date:  2000-12       Impact factor: 19.112

9.  The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery.

Authors:  J H O'Keefe; E H Blackstone; P Sergeant; B D McCallister
Journal:  Eur Heart J       Date:  1998-11       Impact factor: 29.983

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more
  3 in total

1.  National trends in treatment of type 2 diabetes mellitus, 1994-2007.

Authors:  G Caleb Alexander; Niraj L Sehgal; Rachael M Moloney; Randall S Stafford
Journal:  Arch Intern Med       Date:  2008-10-27

2.  Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin.

Authors:  Maryam Ghaffari-Cherati; Abdolkarim Mahrooz; Mohammad Bagher Hashemi-Soteh; Seyyedeh Raheleh Hosseyni-Talei; Ahad Alizadeh; Saeid Mofid Nakhaei
Journal:  J Res Med Sci       Date:  2016-10-18       Impact factor: 1.852

3.  The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.

Authors:  Zahra Kashi; Abdolkarim Mahrooz; Anvarsadat Kianmehr; Ahad Alizadeh
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.